CBFβ enhances De Novo protein biosynthesis of its binding partners HIV-1 Vif and RUNX1 and potentiates the Vif-induced degradation of APOBEC3G

Journal of Virology

Volumn 88, Issue 9, 2014, Pages 4839-4852

  Miyagi, Eri ^a   Kao, Sandra ^a   Yedavalli, Venkat ^a   Strebel, Klaus ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; CORE BINDING FACTOR BETA; GAG PROTEIN; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR RUNX1; VIF PROTEIN; VPU PROTEIN;

ARTICLE; BIOSYNTHESIS; CONTROLLED STUDY; DE NOVO BIOSYNTHESIS; ENZYME DEGRADATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLIC RATE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN METABOLISM; PROTEIN PROCESSING; PROTEIN STABILITY; PROTEIN SYNTHESIS; PROTEIN SYNTHESIS REGULATION; TRANSCRIPTION TERMINATION; VIRUS INFECTIVITY;

CORE BINDING FACTOR ALPHA 2 SUBUNIT; CORE BINDING FACTOR BETA SUBUNIT; CYTIDINE DEAMINASE; HELA CELLS; HUMANS; MOLECULAR CHAPERONES; PROTEIN BIOSYNTHESIS; PROTEOLYSIS; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84897543719     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03359-13     Document Type: Article

References (65)

1. Goila-Gaur R, Strebel K. 2008. HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology 5:51. http://dx.doi.org/10.1186/1742-4690-5-51.
2. Albin JS, Harris RS. 2010. Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics. Expert Rev. Mol. Med. 12:e4. http://dx.doi.org/10.1017/S1462399409001343.
3. Harris RS, Liddament MT. 2004. Retroviral restriction by APOBEC proteins. Nat. Rev. Immunol. 4:868-877. http://dx.doi.org/10.1038/nri1489.
4. Kavli B, Sundheim O, Akbari M, Otterlei M, Nilsen H, Skorpen F, Aas PA, Hagen L, Krokan HE, Slupphaug G. 2002. hUNG2 is the major repair enzyme for removal of uracil from U:A matches, U:G mismatches, and U in single-stranded DNA, with hSMUG1 as a broad specificity backup. J. Biol. Chem. 277:39926-39936. http://dx.doi.org/10.1074/jbc.M207107200.
5. Khan MA, Goila-Gaur R, Kao S, Miyagi E, Walker RC, Jr, Strebel K. 2009. Encapsidation of APOBEC3G into HIV-1 virions involves lipid raft association and does not correlate with APOBEC3G oligomerization. Retrovirology 6:99. http://dx.doi.org/10.1186/1742-4690-6-99.
6. Khan MA, Kao S, Miyagi E, Takeuchi H, Goila-Gaur R, Opi S, Gipson CL, Parslow TG, Ly H, Strebel K. 2005. Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes. J. Virol. 79:5870-5874. http://dx.doi.org/10.1128/JVI.79.9.5870-5874.2005.
7. Svarovskaia ES, Xu H, Mbisa JL, Barr R, Gorelick RJ, Ono A, Freed EO, Hu WS, Pathak VK. 2004. Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs. J. Biol. Chem. 279:35822-35828. http://dx.doi.org/10.1074/jbc.M405761200.
8. Burnett A, Spearman P. 2007. APOBEC3G multimers are recruited to the plasma membrane for packaging into human immunodeficiency virus type 1 virus-like particles in an RNA-dependent process requiring the NC basic linker. J. Virol. 81:5000-5013. http://dx.doi.org/10.1128/JVI.02237-06.
9. Cen S, Guo F, Niu M, Saadatmand J, Deflassieux J, Kleiman L. 2004. The interaction between HIV-1 Gag and APOBEC3G. J. Biol. Chem. 279: 33177-33184. http://dx.doi.org/10.1074/jbc.M402062200.
10. Douaisi M, Dussart S, Courcoul M, Bessou G, Vigne R, Decroly E. 2004. HIV-1 and MLV Gag proteins are sufficient to recruit APOBEC3G into virus-like particles. Biochem. Biophys. Res. Commun. 321:566-573. http://dx.doi.org/10.1016/j.bbrc.2004.07.005.
11. Luo K, Liu B, Xiao Z, Yu Y, Yu X, Gorelick R, Yu XF. 2004. Aminoterminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging. J. Virol. 78:11841-11852. http://dx.doi.org/10.1128/JVI.78.21.11841-11852.2004.
12. Navarro F, Bollman B, Chen H, Konig R, Yu Q, Chiles K, Landau NR. 2005. Complementary function of the two catalytic domains of APOBEC3G. Virology 333:374-386. http://dx.doi.org/10.1016/j.virol.2005.01.011.
13. Schafer A, Bogerd HP, Cullen BR. 2004. Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor. Virology 328:163-168. http://dx.doi.org/10.1016/j.virol.2004.08.006.
14. Zennou V, Perez-Caballero D, Gottlinger H, Bieniasz PD. 2004. APOBEC3G incorporation into human immunodeficiency virus type 1 particles. J. Virol. 78:12058-12061. http://dx.doi.org/10.1128/JVI.78.21.12058-12061.2004.
15. Alce TM, Popi kW. 2004. APOBEC3Gis incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein. J. Biol. Chem. 279: 34083-34086. http://dx.doi.org/10.1074/jbc.C400235200.
16. Kao S, Khan MA, Miyagi E, Plishka R, Buckler-White A, Strebel K. 2003. The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J. Virol. 77:11398-11407. http://dx.doi.org/10.1128/JVI.77.21.11398-11407.2003.
17. Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, Yu XF. 2003. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302:1056-1060. http://dx.doi.org/10.1126/science.1089591.
18. Marin M, Rose KM, Kozak SL, Kabat D. 2003. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat. Med. 9:1398-1403. http://dx.doi.org/10.1038/nm946.
19. Sheehy AM, Gaddis NC, Malim MH. 2003. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 9:1404-1407. http://dx.doi.org/10.1038/nm945.
20. Stopak K, de Noronha C, Yonemoto W, Greene WC. 2003. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell 12:591-601. http://dx.doi.org/10.1016/S1097-2765(03)00353-8.
21. Conticello SG, Harris RS, Neuberger MS. 2003. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr. Biol. 13:2009-2013. http://dx.doi.org/10.1016/j.cub.2003.10.034.
22. Mehle A, Strack B, Ancuta P, Zhang C, McPike M, Gabuzda D. 2004. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J. Biol. Chem. 279: 7792-7798. http://dx.doi.org/10.1074/jbc.M313093200.
23. Niewiadomska AM, Yu XF. 2009. Host restriction of HIV-1 by APOBEC3 and viral evasion through Vif. Curr. Top. Microbiol. Immunol. 339:1-25. http://dx.doi.org/10.1007/978-3-642-02175-6_1.
24. Chen G, He Z, Wang T, Xu R, Yu XF. 2009. A patch of positively charged amino acids surrounding the human immunodeficiency virus type 1 Vif SLVx4Yx9Y motif influences its interaction with APOBEC3G. J. Virol. 83:8674-8682. http://dx.doi.org/10.1128/JVI.00653-09.
25. 174 domains from human immunodeficiency virus type 1 Vif that regulate APOBEC3G and APOBEC3F neutralizing activity. J. Virol. 84:5741-5750. http://dx.doi.org/10.1128/JVI.00079-10.
26. 2(I/L) motif from primate lentivirus Vif proteins that regulate APOBEC3G and APOBEC3F neutralizing activity. J. Virol. 84: 8561-8570. http://dx.doi.org/10.1128/JVI.00960-10.
27. Dang Y, Wang X, Zhou T, York IA, Zheng YH. 2009. Identification of a novel WxSLVK motif in the N terminus of human immunodeficiency virus and simian immunodeficiency virus Vif that is critical for APOBEC3G and APOBEC3F neutralization. J. Virol. 83:8544-8552. http://dx.doi.org/10.1128/JVI.00651-09.
28. He Z, Zhang W, Chen G, Xu R, Yu XF. 2008. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction. J. Mol. Biol. 381:1000-1011. http://dx.doi.org/10.1016/j.jmb.2008.06.061.
29. Pery E, Rajendran KS, Brazier AJ, Gabuzda D. 2009. Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif. J. Virol. 83:2374-2381. http://dx.doi.org/10.1128/JVI.01898-08.
30. Russell RA, Pathak VK. 2007. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J. Virol. 81:8201-8210. http://dx.doi.org/10.1128/JVI.00395-07.
31. Huthoff H, Malim MH. 2007. Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and virion encapsidation. J. Virol. 81:3807-3815. http://dx.doi.org/10.1128/JVI.02795-06.
32. Russell RA, Smith J, Barr R, Bhattacharyya D, Pathak VK. 2009. Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif. J. Virol. 83: 1992-2003. http://dx.doi.org/10.1128/JVI.01621-08.
33. Luo K, Xiao Z, Ehrlich E, Yu Y, Liu B, Zheng S, Yu XF. 2005. Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G. Proc. Natl. Acad. Sci. U. S. A. 102:11444-11449. http://dx.doi.org/10.1073/pnas.0502440102.
34. Mehle A, Thomas ER, Rajendran KS, Gabuzda D. 2006. A zinc-binding region in Vif binds Cul5 and determines cullin selection. J. Biol. Chem. 281:17259-17265. http://dx.doi.org/10.1074/jbc.M602413200.
35. Xiao Z, Ehrlich E, Yu Y, Luo K, Wang T, Tian C, Yu XF. 2006. Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif. Virology 349:290-299. http://dx.doi.org/10.1016/j.virol.2006.02.002.
36. Xiao Z, Xiong Y, Zhang W, Tan L, Ehrlich E, Guo D, Yu XF. 2007. Characterization of a novel Cullin5 binding domain in HIV-1 Vif. J. Mol. Biol. 373:541-550. http://dx.doi.org/10.1016/j.jmb.2007.07.029.
37. Jager S, Kim DY, Hultquist JF, Shindo K, LaRue RS, Kwon E, Li M, Anderson BD, Yen L, Stanley D, Mahon C, Kane J, Franks-Skiba K, Cimermancic P, Burlingame A, Sali A, Craik CS, Harris RS, Gross JD, Krogan NJ. 2011. Vif hijacks CBF-beta to degrade APOBEC3G and promote HIV-1 infection. Nature 481:371-375. http://dx.doi.org/10.1038/nature10693.
38. Zhang W, Du J, Evans SL, Yu Y, Yu XF. 2011. T-cell differentiation factor CBF-beta regulates HIV-1 Vif-mediated evasion of host restriction. Nature 481:376-379. http://dx.doi.org/10.1038/nature10718.
39. Blyth K, Cameron ER, Neil JC. 2005. The RUNX genes: gain or loss of function in cancer. Nat. Rev. Cancer 5:376-387. http://dx.doi.org/10.1038/nrc1607.
40. Hultquist JF, Binka M, LaRue RS, Simon V, Harris RS. 2012. Vif proteins of human and simian immunodeficiency viruses require cellular CBFβ to degrade APOBEC3 restriction factors. J. Virol. 86:2874-2877. http://dx.doi.org/10.1128/JVI.06950-11.
41. Zhou X, Evans SL, Han X, Liu Y, Yu X-F. 2012. Characterization of the interaction of full-length HIV-1 Vif protein with its key regulator CBFβ and CRL5 E3 ubiquitin ligase components. PLoS One 7:e33495. http://dx.doi.org/10.1371/journal.pone.0033495.
42. Hultquist JF, McDougle RM, Anderson BD, Harris RS. 2012. HIV type 1 viral infectivity factor and the RUNX transcription factors interact with core binding factor β on genetically distinct surfaces. AIDS Res. Hum. Retroviruses 28:1543-1551. http://dx.doi.org/10.1089/aid.2012.0142.
43. Kim DY, Kwon E, Hartley PD, Crosby DC, Mann S, Krogan NJ, Gross JD. 2013. CBFβ stabilizes HIV Vif to counteract APOBEC3 at the expense ofRUNX1target gene expression. Mol. Cell 49:632-644. http://dx.doi.org/10.1016/j.molcel.2012.12.012.
44. Du J, Zhao K, Rui Y, Li P, Zhou X, Zhang W, Yu X-F. 2013. Differential requirements for HIV-1 Vif-mediated APOBEC3G degradation and RUNX1-mediated transcription by core binding factor beta. J. Virol. 87: 1906-1911. http://dx.doi.org/10.1128/JVI.02199-12.
45. Zhou J, Zhang Z, Mi Z, Wang X, Zhang Q, Li X, Liang C, Cen S. 2012. Characterization of the interface of the bone marrow stromal cell antigen 2-Vpu protein complex via computational chemistry. Biochemistry 51: 1288-1296. http://dx.doi.org/10.1021/bi2015986.
46. Salter JD, Lippa GM, Belashov IA, Wedekind JE. 2012. Core-binding factor β increases the affinity between human Cullin 5 and HIV-1 Vif within an E3 ligase complex. Biochemistry 51:8702-8704. http://dx.doi.org/10.1021/bi301244z.
47. Karczewski MK, Strebel K. 1996. Cytoskeleton association and virion incorporation of the human immunodeficiency virus type 1 Vif protein. J. Virol. 70:494-507.
48. Kao S, Miyagi E, Khan MA, Takeuchi H, Opi S, Goila-Gaur R, Strebel K. 2004. Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells. Retrovirology 1:27. http://dx.doi.org/10.1186/1742-4690-1-27.
49. Nguyen KL, Llano M, Akari H, Miyagi E, Poeschla EM, Strebel K, Bour S. 2004. Codon optimization of the HIV-1 vpu and vif genes stabilizes their mRNA and allows for highly efficient Rev-independent expression. Virology 319:163-175. http://dx.doi.org/10.1016/j.virol.2003.11.021.
50. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, Martin MA. 1986. Production of acquired immunodeficiency syndromeassociated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291.
51. Walker RC, Jr, Khan MA, Kao S, Goila-Gaur R, Miyagi E, Strebel K. 2010. Identification of dominant negative human immunodeficiency virus type 1 Vif mutants that interfere with the functional inactivation of APOBEC3G by virus-encoded Vif. J. Virol. 84:5201-5211. http://dx.doi.org/10.1128/JVI.02318-09.
52. Cunningham L, Finckbeiner S, Hyde RK, Southall N, Marugan J, Yedavalli VRK, Dehdashti SJ, Reinhold WC, Alemu L, Zhao L, Yeh J-RJ, Sood R, Pommier Y, Austin CP, Jeang K-T, Zheng W, Liu P. 2012. Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBFβ interaction. Proc. Natl. Acad. Sci. U. S. A. 109:14592-14597. http://dx.doi.org/10.1073/pnas.1200037109.
53. Fujita M, Akari H, Sakurai A, Yoshida A, Chiba T, Tanaka K, Strebel K, Adachi A. 2004. Expression of HIV-1 accessory protein Vif is controlled uniquely to be low and optimal by proteasome degradation. Microbes Infect. 6:791-798. http://dx.doi.org/10.1016/j.micinf.2004.04.011.
54. Akari H, Fujita M, Kao S, Khan MA, Shehu-Xhilaga M, Adachi A, Strebel K. 2004. High level expression of human immunodeficiency virus type-1 Vif inhibits viral infectivity by modulating proteolytic processing of the Gag precursor at the p2/nucleocapsid processing site. J. Biol. Chem. 279:12355-12362. http://dx.doi.org/10.1074/jbc.M312426200.
55. Huang G, Shigesada K, Ito K, Wee HJ, Yokomizo T, Ito Y. 2001. Dimerization with PEBP2β protects RUNX1/AML1 from ubiquitinproteasome-mediated degradation. EMBO J. 20:723-733. http://dx.doi.org/10.1093/emboj/20.4.723.
56. Akamatsu Y, Tsukumo S, Kagoshima H, Tsurushita N, Shigesada K. 1997.Asimple screening for mutantDNAbinding proteins: application to murine transcription factor PEBP2α subunit, a founding member of the Runt domain protein family. Gene 185:111-117. http://dx.doi.org/10.1016/S0378-1119(96)00644-0.
57. Wheatley DN, Giddings MR, Inglis MS. 1980. Kinetics of degradation of "short-" and "long-lived" proteins in cultured mammalian cells. Cell Biol. Int. Rep. 4:1081-1090. http://dx.doi.org/10.1016/0309-1651 (80)90045-4.
58. Turner GC, Varshavsky A. 2000. Detecting and measuring cotranslational protein degradation in vivo. Science 289:2117-2120. http://dx.doi.org/10.1126/science.289.5487.2117.
59. Rabson A, Daugherty D, Venkatesan S, Boulukos KE, Benn S, Folks TM, Feorino P, Martin MA. 1985. Transcription of novel open reading frames of AIDS retrovirus during infection of lymphocytes. Science 229: 1388-1390. http://dx.doi.org/10.1126/science.2994220.
60. Karn J, Stoltzfus CM. 2012. Transcriptional and posttranscriptional regulation of HIV-1 gene expression. Cold Spring Harb. Perspect. Med. 2:a006916. http://dx.doi.org/10.1101/cshperspect.a006916.
61. Tahirov TH, Inoue-Bungo T, Morii H, Fujikawa A, Sasaki M, Kimura K, Shiina M, Sato K, Kumasaka T, Yamamoto M, Ishii S, Ogata K. 2001. Structural analyses of DNA recognition by the AML1/Runx-1 Runt do-main and its allosteric control by CBFβ. Cell 104:755-767. http://dx.doi.org/10.1016/S0092-8674(01)00271-9.
62. Kao S, Goila-Gaur R, Miyagi E, Khan MA, Opi S, Takeuchi H, Strebel K. 2007. Production of infectious virus and degradation of APOBEC3G are separable functional properties of human immunodeficiency virus type 1 Vif. Virology 369:329-339. http://dx.doi.org/10.1016/j.virol.2007.08.005.
63. Tscherne JS, Pestka S. 1975. Inhibition of protein synthesis in intact HeLa cells. Antimicrob. Agents Chemother. 8:479-487. http://dx.doi.org/10.1128/AAC.8.4.479.
64. Schubert U, Anton LC, Gibbs J, Norbury CC, Yewdell JW, Bennink JR. 2000. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 404:770-774. http://dx.doi.org/10.1038/35008096.
65. Klase Z, Yedavalli VSRK, Houzet L, Perkins M, Maldarelli F, Brenchley J, Strebel K, Liu P, Jeang KT. Activation of HIV-1 from latent infection via synergy of RUNX1 inhibitor Ro5-3335 and SAHA. PLoS Pathog., in press.